Catalyst Pharmaceuticals Inc Total Liabilities
Catalyst Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) has total liabilities worth $134.91 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Catalyst Pharmaceuticals Inc (CPRX) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Catalyst Pharmaceuticals Inc (2002–2025)
Total liabilities of Catalyst Pharmaceuticals Inc from 2002 to 2025. This chart illustrates how Catalyst Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Catalyst Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Catalyst Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Catalyst Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Formosa Sumco Technology Corp
TW:3532
|
Taiwan | NT$26.77 Billion |
|
Indofood Cbp Sukses Makmur Tbk
JK:ICBP
|
Indonesia | Rp61.06 Trillion |
|
Jiangxi Zhengbang Technology Co Ltd
SHE:002157
|
China | CN¥9.41 Billion |
|
Talkweb Information System Co Ltd
SHE:002261
|
China | CN¥1.53 Billion |
|
Tidewater Inc
NYSE:TDW
|
USA | $977.97 Million |
|
Global Health Limited
NSE:MEDANTA
|
India | Rs-39.84 Billion |
|
Harvey Norman Holdings Ltd
AU:HVN
|
Australia | AU$3.82 Billion |
|
Wuchan Zhongda Group Co Ltd
SHG:600704
|
China | CN¥164.05 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Catalyst Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CPRX current and non-current assets.
Liquidity & Leverage Metrics
Catalyst Pharmaceuticals Inc Total Liabilities Ratios Explained
Catalyst Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Catalyst Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Catalyst Pharmaceuticals Inc (2002–2025)
The table below shows the annual total liabilities of Catalyst Pharmaceuticals Inc from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $152.54 Million | +23.24% |
| 2024-12-31 | $123.78 Million | +50.52% |
| 2023-12-31 | $82.23 Million | +9.34% |
| 2022-12-31 | $75.21 Million | +142.95% |
| 2021-12-31 | $30.96 Million | +36.04% |
| 2020-12-31 | $22.76 Million | -8.04% |
| 2019-12-31 | $24.75 Million | +156.01% |
| 2018-12-31 | $9.67 Million | +118.51% |
| 2017-12-31 | $4.42 Million | +84.48% |
| 2016-12-31 | $2.40 Million | -48.16% |
| 2015-12-31 | $4.63 Million | -46.63% |
| 2014-12-31 | $8.67 Million | +117.83% |
| 2013-12-31 | $3.98 Million | +83.57% |
| 2012-12-31 | $2.17 Million | -12.92% |
| 2011-12-31 | $2.49 Million | +693.27% |
| 2010-12-31 | $313.71K | -9.99% |
| 2009-12-31 | $348.52K | -76.34% |
| 2008-12-31 | $1.47 Million | +312.35% |
| 2007-12-31 | $357.17K | -53.79% |
| 2006-12-31 | $772.85K | +125.33% |
| 2005-12-31 | $342.99K | +405.88% |
| 2004-12-31 | $67.80K | +1.65% |
| 2002-12-31 | $66.70K | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more